Bicycle Therapeutics Plc ADR (BCYC) Stock Price, Quote & News

Company Profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing t...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 1223 261 503

Website: www.bicycletherapeutics.com

Address:

Portway Building, Blocks A & B Granta Park Great Abington, Cambridge, United Kingdom

eladfff Sep. 10 at 9:44 PM

$BCYC Cutting 25% of workforce but increasing board size by 25%. Ok. Nice round numbers anyway. Like this nice round -50% YTD. With green XBI and IBB. Doesn't even include the December Disaster.

0 · Reply

nikitatrades Sep. 9 at 1:49 PM

$BCYC #BicycleTx's lead drug, zelenectide, shows promising efficacy (45% ORR) & a safer profile vs. PADCEV in bladder cancer, with less neuropathy & skin toxicity. Pivotal Phase II/III data readout & FDA update due Q4. Strong cash position ($700M+) into 2028. 🚴‍♂️🩺 #Biotech

0 · Reply

bigtuna7 Sep. 8 at 1:57 PM

$BCYC Looks to be basing, not getting my hopes up.... @SmartestMoney shine some light back on the bike!

1 · Reply

Strangperson Sep. 4 at 4:21 PM

$BCYC

0 · Reply

NVDAMillionaire Sep. 4 at 12:17 PM

$BCYC Great piece that accurately captures BCYC's current position. So if you want to refresh your understanding of BCYC or learn about BCYC for the first time, this is essential reading. https://beyondspx.com/quote/BCYC/bicycle-therapeutics-pedaling-towards-precision-oncology-with-a-differentiated-platform-nasdaq-bcyc#analysis

0 · Reply

eladfff Sep. 2 at 6:36 PM

$BCYC Another $0.50+ fade

0 · Reply

eladfff Sep. 2 at 6:35 PM

$BCYC fade through today's AND Friday's gains, ha!

0 · Reply

eladfff Aug. 28 at 6:40 PM

$BCYC fades almost every single day. The Daily Fade. Has closed closer to its low than its high 25 of the last 29 sessions

0 · Reply

Stmkr Aug. 28 at 1:45 AM

$BCYC https://pmc.ncbi.nlm.nih.gov/articles/PMC11983102/

0 · Reply

Stmkr Aug. 28 at 1:40 AM

$BCYC Nice to see IONS still actively progressing BCYC molecules for targted delivery of siRNA

0 · Reply

Bicycle Therapeutics Plc (BCYC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 4:05 PM EDT - 5 days ago

Bicycle Therapeutics Strengthens Board of Directors with New Appointments

Aug 8, 2025, 7:00 AM EDT - 5 weeks ago

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Jul 2, 2025, 4:05 PM EDT - 2 months ago

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 22, 2025, 5:05 PM EDT - 4 months ago

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

May 1, 2025, 7:00 AM EDT - 4 months ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Apr 22, 2025, 3:47 AM EDT - 5 months ago

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 6 months ago

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Feb 25, 2025, 7:00 AM EST - 7 months ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 7 months ago

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 2, 2025, 5:26 AM EST - 7 months ago

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data

Jan 13, 2025, 7:00 AM EST - 8 months ago

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Jan 9, 2025, 7:00 AM EST - 8 months ago

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 6:30 PM EST - 9 months ago

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Dec 10, 2024, 7:00 AM EST - 9 months ago

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Nov 25, 2024, 5:30 PM EST - 10 months ago

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Nov 12, 2024, 7:00 AM EST - 10 months ago

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 7, 2024, 10:04 AM EST - 11 months ago

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern

Oct 31, 2024, 7:00 AM EDT - 11 months ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 23, 2024, 7:00 AM EDT - 11 months ago

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

Oct 16, 2024, 7:00 AM EDT - 11 months ago

Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Sep 6, 2024, 1:37 PM EDT - 1 year ago

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Aug 20, 2024, 7:37 AM EDT - 1 year ago

Bicycle Therapeutics Is Looking Increasingly Attractive

Aug 6, 2024, 7:05 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

Aug 6, 2024, 7:00 AM EDT - 1 year ago

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

BSY MASS MLI NJR OFIX QBTS SMMT

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024

May 23, 2024, 5:05 PM EDT - 1 year ago

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

May 23, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing

May 2, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

Apr 24, 2024, 10:05 AM EDT - 1 year ago

Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 25, 2024, 1:07 PM EDT - 1 year ago

2 More Potential Biotech Buyout Targets

AZN BMY EXEL LLY MRK NVS TAK

Mar 12, 2024, 12:09 PM EDT - 1 year ago

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 5, 2024, 4:35 PM EST - 1 year ago

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

Feb 20, 2024, 7:05 AM EST - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:00 AM EST - 1 year ago

Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 14, 2023, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Nov 30, 2023, 7:00 AM EST - 1 year ago

Bicycle Therapeutics to Host R&D Day on December 14

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

Oct 19, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer

Oct 19, 2023, 4:00 AM EDT - 2 years ago

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 3, 2023, 6:59 AM EDT - 2 years ago

Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 31, 2023, 7:07 PM EDT - 2 years ago

Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due

Jul 18, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

eladfff Sep. 10 at 9:44 PM

$BCYC Cutting 25% of workforce but increasing board size by 25%. Ok. Nice round numbers anyway. Like this nice round -50% YTD. With green XBI and IBB. Doesn't even include the December Disaster.

0 · Reply

nikitatrades Sep. 9 at 1:49 PM

0 · Reply

bigtuna7 Sep. 8 at 1:57 PM

$BCYC Looks to be basing, not getting my hopes up.... @SmartestMoney shine some light back on the bike!

1 · Reply

Strangperson Sep. 4 at 4:21 PM

$BCYC

0 · Reply

NVDAMillionaire Sep. 4 at 12:17 PM

0 · Reply

eladfff Sep. 2 at 6:36 PM

$BCYC Another $0.50+ fade

0 · Reply

eladfff Sep. 2 at 6:35 PM

$BCYC fade through today's AND Friday's gains, ha!

0 · Reply

eladfff Aug. 28 at 6:40 PM

$BCYC fades almost every single day. The Daily Fade. Has closed closer to its low than its high 25 of the last 29 sessions

0 · Reply

Stmkr Aug. 28 at 1:45 AM

$BCYC https://pmc.ncbi.nlm.nih.gov/articles/PMC11983102/

0 · Reply

Stmkr Aug. 28 at 1:40 AM

$BCYC Nice to see IONS still actively progressing BCYC molecules for targted delivery of siRNA

0 · Reply

SQUEAKSBANDIT Aug. 27 at 6:03 PM

$BCYC reminds me a bit of $QURE different indications/technology, but had decent results and was ignored by the market for the better part of a year had a negative ev for awhile but worked out well for those who rode it out

0 · Reply

Fred378 Aug. 26 at 12:29 AM

$BCYC

0 · Reply

eladfff Aug. 22 at 7:51 PM

$BCYC Point72 still selling, constant weight pushing down. Sold 2M shares in 2nd Q and had 2M left, probably take the whole 3rd Q before they're done and that selling pressure is relieved. Probably other funds in no rush to help Point72 by putting out big bids

2 · Reply

SQUEAKSBANDIT Aug. 21 at 12:22 AM

$BCYC https://firstwordpharma.com/story/5921472 bakers bought very large AFTER this data hit in dec shares down over 50% since they bought

0 · Reply

SQUEAKSBANDIT Aug. 20 at 6:28 PM

$BCYC i'm kinda shocked that we have a chance to add under 7 despite the filing the brothers haven't sold a share and aren't committed to sell any

1 · Reply

SQUEAKSBANDIT Aug. 20 at 6:11 PM

$BCYC broke under 7 on anemic volume took some

0 · Reply

eladfff Aug. 19 at 8:20 PM

$BCYC Ready for fresh lows. Just a little hard to believe with Julian and Felix having put literally half a billion dollars into this from $20/sh. Head-scratcher. Possibly those clowns at Point-72 are still finishing up selling the several million shares they bought less than a year ago. They had sold 3M of their 5M shares by the end of the 2nd Q.

1 · Reply

eladfff Aug. 14 at 8:17 PM

$BCYC Only a 50¢ fade today

0 · Reply

SQUEAKSBANDIT Aug. 14 at 7:52 PM

$BCYC anyone been trading the intraday volatility this name has been such a laggard but money can be made flipping moves fast

0 · Reply

eladfff Aug. 14 at 3:39 AM

$BCYC 77¢ fade after acting for half an hour like it wanted to participate

0 · Reply

eladfff Aug. 12 at 8:51 PM

$BCYC Absolute garbage with XBI ripping. BT1718 quietly abandoned, BT8009 efficacy looks inferior to Padcev in mUC, BT5528 and BT7480 early data looks terrible, Genentech partnership termination, layoffs, mixed shelf filing for an amount greater than current MC, BB's filing to be able to sell their 30M shares, downgrades and PT cuts... Seems very bad rt now. I guess that makes the question whether they're approaching "max badness". Or whether there's worse yet to come.

0 · Reply

anachartanalyst Aug. 12 at 2:02 PM

$BCYC https://anachart.com/wp-content/uploads/ana_temp/1755007338_soc-img.jpg

0 · Reply

Market Cap	486.16M
Revenue (ttm)	35.28M
Net Income (ttm)	-169.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-479.11%
Debt to Equity Ratio	0.00

Volume	370,900
Avg Vol	260,006
Day's Range	N/A - N/A
Shares Out	69.25M
Stochastic %K	36%
Beta	1.41
Analysts	Strong Sell
Price Target	$24.90